Spectral AI, Inc. Q3'26 Financial Results Conference Call - SPECTRAL AI INC

Explicit Guidance:

• FY2026 Research and Development (R&D) revenue updated to approximately $13 million (down from prior guidance of $18.5 million), excluding DeepView AI device sales or new government awards. The reduction is attributed to the completion of the M-TEC program and the timing of BARDA cost-share revenue shifting into future periods.
• No specific guidance provided for Commercial device sales revenue, Operating Expenses (OpEx), Net Income, or Free Cash Flow for the upcoming quarters or FY2027.
• No guidance provided for capital expenditures (CapEx) or share count changes.

Business-Segment Outlook:

• DeepView AI System: Initial manufacturing of 30 units completed; initial BARDA-supported deployments to U.S. burn centers expected in 2026.
• Sales Footprint: Goal to expand national sales footprint in the U.S. by end of FY2026, with plans to support more consistent burn wound assessments across the U.S. and abroad.
• Reimbursement & Label:
  • NTAP Application: Awaiting determination by August 2027; if approved, would provide a payment code of $2,750 per patient for hospital systems, with a potential 2–3 year term beginning October 2027.
  • CPT Coding: Current CPT-3 coding supported by local MAC pricing starting January 1, 2027; working to migrate to CPT-1 coding supported by the TNT study.
  • Label Expansion: UK self-funded study for head, hands, and feet burns currently enrolled 10 patients; total body surface area calculation expansion ongoing.
• Revenue Model: Commercial model pairs device purchases/leases with recurring software/service revenue under minimum three-year terms; commercial sales expected to yield higher margins than development work as installed base grows.
• Clinical Studies:
  • TNT Study (U.S.): Commencing at 4–5 centers in early December 2026; expanding to 12 centers by end of Q1 2027 to evaluate impact on surgical precision, treatment decisions, and hospital length of stay.
  • UK Label Study: Site initiation completed at 4 centers; study ongoing.

Market and Competitive Outlook:

• Pricing Strategy: Pricing calibrated via leading consulting and KOL feedback to balance adoption at large burn centers and community/focused centers; economic modeling targets cost reductions and reimbursement synergy.
• Go-to-Market: KOL-driven approach targeting leading burn physicians and emergency room physicians; leveraging on-site demonstrations to advance procurement at centers with limited prior experience.
• Access Goal: Strategy focused on ensuring equitable access to advanced burn assessment regardless of geographic location or socioeconomic status (urban vs. rural).
• International Expansion: Awaiting UKCA burn assessment approval update (reflecting new algorithm/hardware) with launch expected in early 2027 across the UK, Australia, or GCC countries.

Macro / Industry Outlook:

• Regulatory: FDA clearance obtained May 2026; UKCA approval update expected early 2027.
• Reimbursement: Anticipated pathway advancement for physician reimbursement effective January 1, 2027; NTAP resolution critical for hospital adoption in October 2027.
• Clinical Adoption: Focus on integrating DeepView AI into standard clinical protocols for everyday burn care and mass casualty preparedness.

Strategic Initiatives:

• Manufacturing: Completed initial production run of 30 DeepView AI systems for BARDA deployments.
• Capital Allocation: Maintaining disciplined capital deployment with $11.2 million cash on hand (as of Sept 30, 2026) and access to $90 million in non-dilutive funding from BARDA.
• Debt Management: Avenue facility fully drawn at $15 million; interest-only payments through March 2027, maturity in March 2028.
• International: Launching commercial placements outside the U.S. pending UKCA approval in early 2027.
• Cost Structure: R&D expenses rising (to $2.0M in Q3) due to UK label study; G&A expenses declining due to lower legal fees; S&M expenses increasing to support commercial launch.

Risks and Headwinds to Outlook:

• Regulatory Timelines: Delays in UKCA approval or NTAP determination could push international sales and reimbursement pathways beyond early 2027.
• Adoption Barriers: Procurement cycles at hospital systems and burn centers remain a hurdle to initial deployment.
• Revenue Timing: Shift in BARDA cost-share revenue into future periods reduces current R&D revenue visibility.
• Financial Constraints: Transition from research to commercial enterprise carries execution risk; reliance on non-dilutive funding and debt maturity in March 2028 requires careful cash management.
• Margin Volatility: Gross margins (currently 27.2%) remain depressed by BARDA cost-sharing structure until commercial scale is achieved.

Management Tone on the Future:

• Confidence Level: Cautiously optimistic; management expresses "encouragement" regarding clinical engagement and patient enrollment but acknowledges the "disciplined" nature of the transition from R&D to commercial enterprise.
• Hedges: Explicitly states that forward-looking statements are "not guarantees" and involve "known and unknown risks"; emphasizes that results could differ materially due to factors outside company control.
• Strategic Focus: Strong emphasis on "building processes," "learning from deployments," and establishing a "sustainable" business rather than rushing sales.

Miscellaneous:

• Share Count: 32.2 million shares outstanding as of September 30, 2026.
• Dividend/Buyback: No mention of dividends or share buyback plans.
• M&A: No mention of acquisition or partnership activities beyond existing BARDA and clinical collaborations.